Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.

Détails

Ressource 1Télécharger: Thiebaut et al_Autophagy_2022.pdf (6262.66 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: CC BY 4.0
ID Serval
serval:BIB_92B2E7EE737F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Périodique
Autophagy
Auteur⸱e⸱s
Thiebaut A.M., Buendia I., Ginet V., Lemarchand E., Boudjadja M.B., Hommet Y., Lebouvier L., Lechevallier C., Maillasson M., Hedou E., Déglon N., Oury F., Rubio M., Montaner J., Puyal J., Vivien D., Roussel B.D.
ISSN
1554-8635 (Electronic)
ISSN-L
1554-8627
Statut éditorial
Publié
Date de publication
06/2022
Peer-reviewed
Oui
Volume
18
Numéro
6
Pages
1297-1317
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Cerebral ischemia is a pathology involving a cascade of cellular mechanisms, leading to the deregulation of proteostasis, including macroautophagy/autophagy, and finally to neuronal death. If it is now accepted that cerebral ischemia induces autophagy, the effect of thrombolysis/energy recovery on proteostasis remains unknown. Here, we investigated the effect of thrombolysis by PLAT/tPA (plasminogen activator, tissue) on autophagy and neuronal death. In two in vitro models of hypoxia reperfusion and an in vivo model of thromboembolic stroke with thrombolysis by PLAT/tPA, we found that ischemia enhances neuronal deleterious autophagy. Interestingly, PLAT/tPA decreases autophagy to mediate neuroprotection by modulating the PI3K-AKT-MTOR pathways both in vitro and in vivo. We identified IGF1R (insulin-like growth factor I receptor; a tyrosine kinase receptor) as the effective receptor and showed in vitro, in vivo and in human stroke patients and that PLAT/tPA is able to degrade IGFBP3 (insulin-like growth factor binding protein 3) to increase IGF1 (insulin-like growth factor 1) bioavailability and thus IGF1R activation.Abbreviations: AKT/protein kinase B: thymoma viral proto-oncogene 1; EGFR: epidermal growth factor receptor; Hx: hypoxia; IGF1: insulin-like growth factor 1; IGF1R: insulin-like growth factor I receptor; IGFBP3: insulin-like growth factor binding protein 3; Ka: Kainate; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MAPK/ERK: mitogen-activated protein kinase; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; OGD: oxygen and glucose deprivation; OGD <sub>reox</sub> : oxygen and glucose deprivation + reoxygentation; PepA: pepstatin A1; PI3K: phosphoinositide 3-kinase; PLAT/tPA: plasminogen activator, tissue; PPP: picropodophyllin; SCH77: SCH772984; ULK1: unc-51 like kinase 1; Wort: wortmannin.
Mots-clé
Autophagy, Brain Ischemia/drug therapy, Glucose/pharmacology, Humans, Hypoxia, Insulin-Like Growth Factor Binding Protein 3/metabolism, Insulin-Like Growth Factor Binding Protein 3/pharmacology, Insulin-Like Growth Factor I/metabolism, Mechanistic Target of Rapamycin Complex 1/metabolism, Oxygen/pharmacology, Phosphatidylinositol 3-Kinases/metabolism, Proto-Oncogene Proteins c-akt/metabolism, Signal Transduction, Stroke/drug therapy, TOR Serine-Threonine Kinases/metabolism, Thrombolytic Therapy, Tissue Plasminogen Activator/metabolism, Tissue Plasminogen Activator/pharmacology, IGF1R, IGFBP3, LC3, MTORC1, SQSTM1/p62, stroke
Pubmed
Web of science
Financement(s)
Fonds national suisse / Projets / 310030-182332
Fonds national suisse / Projets / 310030-163064
Création de la notice
15/09/2021 15:32
Dernière modification de la notice
11/02/2023 8:13
Données d'usage